70 patients, DERMA-ER-DC 04 trial

These 70 patients were evaluated in the DERMA-ER-DC 04 clinical trial of DC-based therapy of melanoma patients (multipeptide loaded cytokine matured moDC +/- CD40L activation). The analysis for the first time showed a clinical correlation of induced immune responses as measured in the blood with outcome, as there have been so far statistically significantly less events in stage III patients showing good CTL reponses (IFN-y Elispot) to multiple class I and II peptides compared to low responders of the stage III cohort. Additional in vitro maturation of DC by CD40L (leucine zipper, Immunex) did not result in better immunity compard to standard cytokine cocktail matured DC.

created over 15 years ago (2 March 2009)    last modified over 13 years ago (28 September 2011)   [ RDF ]   [ RelFinder ]